128 related articles for article (PubMed ID: 38379256)
1. Successful treatment of checkpoint inhibitor-associated bullous pemphigoid with dupilumab in a patient with angiosarcoma.
Hansen I; Gebhardt C; Booken N; Schneider SW
J Dtsch Dermatol Ges; 2024 Apr; 22(4):587-589. PubMed ID: 38379256
[No Abstract] [Full Text] [Related]
2. Hickam versus Ockham: atopic dermatitis and bullous pemphigoid or pemphigoid nodularis? Dupilumab solves the problem.
Mutton T; Bocchi C; Gaban A; Marzola E; Schettini N; Borghi A
Ital J Dermatol Venerol; 2024 Jun; 159(3):361-363. PubMed ID: 38695597
[No Abstract] [Full Text] [Related]
3. Treatment of Bullous Pemphigoid With Dupilumab: A Case Series of 30 Patients.
Miller AC; Temiz LA; Adjei S; Duran MA; Sassmannshausen J; Dominguez A; Thomas C; Schmidt JD; Bernhardt M; Doolittle-Amieva CJ; Moshiri AS; Thompson AJ; Pyoung Kim-Lim P; Mattia AV; Tyring SK
J Drugs Dermatol; 2024 Jun; 23(6):e144-e148. PubMed ID: 38834228
[TBL] [Abstract][Full Text] [Related]
4. Concomitant use of dupilumab with glucocorticoid in bullous pemphigoid reduces disease severity: A preliminary study.
Hu L; Huang R; Jiang F; You S; Wu Q
Immun Inflamm Dis; 2023 Jul; 11(7):e924. PubMed ID: 37506153
[TBL] [Abstract][Full Text] [Related]
5. Dupilumab for the treatment of nivolumab-induced bullous pemphigoid: a case report and review of the literature.
Klepper EM; Robinson HN
Dermatol Online J; 2021 Sep; 27(9):. PubMed ID: 34755978
[TBL] [Abstract][Full Text] [Related]
6. Long-term efficacy and safety of dupilumab for severe bullous pemphigoid: A prospective cohort study.
Huang D; Zhang Y; Yu Y; Jiang Y; Kong L; Ding Y; Shi Y; Gao Y
Int Immunopharmacol; 2023 Dec; 125(Pt A):111157. PubMed ID: 37925949
[TBL] [Abstract][Full Text] [Related]
7. Dupilumab combined with low-dose systemic steroid therapy improves efficacy and safety for bullous pemphigoid.
Yang J; Gao H; Zhang Z; Tang C; Chen Z; Wang L; Yang F; Chen S; He S; Liu S; Tang L; Xu Y; Hu Y; Ma L; Zhao Y; Luo X
Dermatol Ther; 2022 Aug; 35(8):e15648. PubMed ID: 35715972
[TBL] [Abstract][Full Text] [Related]
8. The Successful Treatment of COVID-19-Induced Bullous Pemphigoid With Dupilumab.
Savoldy MA; Tadicherla T; Moureiden Z; Ayoubi N; Baldwin BT
Cureus; 2022 Oct; 14(10):e30541. PubMed ID: 36415388
[TBL] [Abstract][Full Text] [Related]
9. Rituximab, Omalizumab, and Dupilumab Treatment Outcomes in Bullous Pemphigoid: A Systematic Review.
Cao P; Xu W; Zhang L
Front Immunol; 2022; 13():928621. PubMed ID: 35769474
[TBL] [Abstract][Full Text] [Related]
10. A Rare Case of Bullous Pemphigoid Secondary to Checkpoint Inhibitor Immunotherapy: A Tense Situation.
Wesolow JT; Jalali S; Clark LD
Cureus; 2021 Jul; 13(7):e16169. PubMed ID: 34367779
[TBL] [Abstract][Full Text] [Related]
11. Immune checkpoint inhibitor-induced bullous pemphigoid is characterized by interleukin (IL)-4 and IL-13 expression and responds to dupilumab treatment.
Shipman WD; Singh K; Cohen JM; Leventhal J; Damsky W; Tomayko MM
Br J Dermatol; 2023 Aug; 189(3):339-341. PubMed ID: 37140007
[No Abstract] [Full Text] [Related]
12. The efficacy and safety of dupilumab combined with methylprednisolone in the treatment of bullous pemphigoid in China.
Qi W; Rushan X
Int Immunopharmacol; 2023 May; 118():110050. PubMed ID: 37003187
[TBL] [Abstract][Full Text] [Related]
13. Case report: Dupilumab for the treatment of bullous pemphigoid.
Wang M; Wang J; Shi B
Dermatol Ther; 2022 Jul; 35(7):e15541. PubMed ID: 35478478
[TBL] [Abstract][Full Text] [Related]
14. Successful treatment of bullous pemphigoid with dupilumab: a case and brief review of the literature.
Saleh M; Reedy M; Torok H; Weaver J
Dermatol Online J; 2021 Apr; 27(4):. PubMed ID: 33999579
[TBL] [Abstract][Full Text] [Related]
15. Successful treatment of eczema-like bullous pemphigoid and typical bullous pemphigoid with dupilumab: two case reports.
Xu Y; Song W; Cai Y; Huang R; Wei J; Liu H; Peng X; Zeng K; Li C
Int J Dermatol; 2023 Mar; 62(3):e144-e146. PubMed ID: 36214412
[No Abstract] [Full Text] [Related]
16. Treatment of bullous pemphigoid with dupilumab: Dupilumab exerts its effect by primarily suppressing T-helper 2 cytokines.
Takamura S; Teraki Y
J Dermatol; 2022 Sep; 49(9):845-850. PubMed ID: 35538742
[TBL] [Abstract][Full Text] [Related]
17. Use of Dupilumab in Bullous Pemphigoid: Where Are We Now?
Russo R; Capurro N; Cozzani E; Parodi A
J Clin Med; 2022 Jun; 11(12):. PubMed ID: 35743438
[TBL] [Abstract][Full Text] [Related]
18. Successful Treatment of Psoriasis Combined with Bullous Pemphigoid with Dupilumab: A Case Report.
Liu JH; Gao Q; Ma WY; Cheng ZL; Luo NN; Hao PS
Clin Cosmet Investig Dermatol; 2023; 16():1583-1587. PubMed ID: 37359718
[TBL] [Abstract][Full Text] [Related]
19. Nine cases of refractory bullous pemphigoid treated with dupilumab and literature review.
Liang J; Abulikemu K; Maolidan ; Hu F; Zhao J; Qiu Y; Wang Q; Sang Y; Hong Y; Kang X
Int Immunopharmacol; 2023 Mar; 116():109788. PubMed ID: 36731156
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of Dupilumab in Patients With Bullous Pemphigoid.
Zhao L; Wang Q; Liang G; Zhou Y; Yiu N; Yang B; Zhang G; Li W; Feng S; Shang P; Chen X; Zhu X; Zheng J; Pan M; Wang M
JAMA Dermatol; 2023 Sep; 159(9):953-960. PubMed ID: 37531116
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
